Antifungal drugs

Side Effects of Drugs Annual

Volumn 24, Issue , 2001, Pages 314-329

  Groll, Andreas H ^a   Chiou, Christine ^a   Walsh, Thomas J ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 35648959377     PISSN: 03786080     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0378-6080(01)80032-5     Document Type: Article

References (95)

1. Degreef H Del Palacio A Mygind S Ginter G Pinto Soares A Zuluaga De Cadena A Randomized double-blind comparison of short-term itraconazole and terbinafine therapy for toenail onychomycosis Acta Dermatol Venereol 79 1999 221 223
2. Evans EG Sigurgeirsson B Double blind, randomised study of continuous terbinafine compared with intermittent itraconazole in treatment of toenail onychomycosis. The LION Study Group Br Med J 318 1999 1031 1035
3. Sigurgeirsson B Billstein S Rantanen T Ruzicka T di Fonzo E Vermeer BJ Goodfield MJD Evans EGV LION Study: efficacy and tolerability of continuous terbinafine (Lamisil) compared to intermittent itraconazole in the treatment of toenail onychomycosis Br J Dermatol Suppl 141 Suppl 56 1999 5 14
4. Shapiro M Li LJ Miller J Terbinafine-induced neutropenia Br J Dermatol 140 1999 1196 1197
5. Bennett ML Jorizzo JL White WL Generalized pustular eruptions associated with oral terbinafine Int J Dermatol. 38 1999 596 600
6. Pauluzzi P Boccucci N Inverse psoriasis induced by terbinafine Acta Dermatol Venereol 79 1999 389
7. Krafchik B Pelletier J An open study of tinea capitis in 50 children treated with a 2-week course of oral terbinafine J Am Acad Dermatol 41 1999 60 63
8. Gill J Sprenger HR Ralph ED Sharpe MD Hepatotoxicity possibly caused by amphotericin B Ann Pharmacother 33 1999 683 685
9. Wingard JR Kubilis P Lee L Yee G White M Walshe L Bowden R Anaissie E Hiemenz J Lister J Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis Clin Infect Dis 29 1999 1402 1407
10. Nath CE Shaw PJ Gunning R McLachlan AJ Earl JW Amphotericin B in children with malignant disease: a comparison of the toxicities and pharmacokinetics of amphotericin B administered in dextrose versus lipid emulsion Antimicrob Agents Chemother 43 1999 1417 1423
11. Thakur CP Singh RK Hassan SM Kumar R Narain S Kumar A Amphotericin B deoxycholate treatment of visceral leishmaniasis with newer modes of administration and precautions: a study of 938 cases Trans R Soc Trop Med Hyg 93 1999 319 323
12. Schwartz S Behre G Heinemann V Wandt H Schilling E Arning M Trittin A Kern WV Boenisch O Bosse D Lenz K Ludwig WD Hiddemann W Siegert W Beyer J Aerosolized amphotericin B inhalations as prophylaxis of invasive Aspergillus infections during prolonged neutropenia: results of a prospective randomized multicenter trial Blood 93 1999 3654 3661
13. Herbrecht R Letscher V Andres E Cavalier A Safety and efficacy of amphotericin B colloidal dispersion. An overview Chemotherapy 45 Suppl 1 1999 67 76
14. Noskin G Pietrelli L Gurwith M Bowden R Treatment of invasive fungal infections with amphotericin B colloidal dispersion in bone marrow transplant recipients Bone Marrow Transplant 23 1999 697 703
15. Linden P Lee L Walsh TJ Retrospective analysis of the dosage of amphotericin B lipid complex for the treatment of invasive fungal infections Pharmacotherapy 19 1999 1261 1268
16. Singhal S Hastings JG Mutimer DJ Safety of high-dose amphotericin B lipid complex Bone Marrow Transplant 24 1999 116 117
17. Cook G Franklin IM Adverse drug reactions associated with the administration of amphotericin B lipid complex Bone Marrow Transplant 23 1999 1325 1326
18. Ringden O Jonsson V Hansen M Tollemar J Jacobsen N Severe and common side-effects of amphotericin B lipid complex Bone Marrow Transplant 22 1998 733 734
19. Martino R Subira M Sureda A Sierra J Amphotericin B lipid complex at 3 mg/kg/day for treatment of invasive fungal infections in adults with haematological malignancies J Antimicrob Chemother 44 1999 569 572
20. Martino R Subira M Domingo-Albos A Sureda A Sierra J Low-dose amphotericin B lipid complex for the treatment of persistent fever of unknown origin in patients with hematologic malignancies and prolonged neutropenia Chemotherapy 45 1999 205 212
21. Groll AH Piscitelli SC Walsh TJ Clinical pharmacology of systemic antifungal agents: a comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development Adv Pharmacol 44 1998 343 500
22. Rowles DM Fraser SL Amphotericin B lipid complex (ABLC)-associated hypertension: case report and review Clin Infect Dis. 29 1999 1564 1565
23. Walsh TJ Seibel NL Arndt C Harris RE Dinubile MJ Reboli A Hiemenz J Chanock SJ Amphotericin B lipid complex in pediatric patients with invasive fungal infections Pediatr Infect Dis J 18 1999 702 708
24. Walsh TJ Finberg RW Arndt C Hiemenz J Schwartz C Bodensteiner D Pappas P Seibel N Greenberg RN Dummer S Schuster M Holcenberg JS Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group New Engl J Med. 340 1999 764 771
25. Kelsey SM Goldman JM McCann S Newland AC Scarffe JH Oppenheim BA Mufti GJ Liposomal amphotericin (AmBisome) in the prophylaxis of fungal infections in neutropenic patients: a randomised, double-blind, placebo-controlled study Bone Marrow Transplant 23 1999 163 168
26. Cesaro S Calore E Messina C Zanesco L Allergic reaction to the liposomal component of liposomal amphotericin B Supportive Care Cancer 7 1999 284 286
27. Nucci M Loureiro M Silveira F Casali AR Bouzas LF Velasco E Spector N Pulcheri W Comparison of the toxicity of amphotericin B in 5% dextrose with that of amphotericin B in fat emulsion in a randomized trial with cancer patients Antimicrob Agents Chemother 43 1999 1445 1448
28. Gubbins PO McConnell SA Penzak SR Antifungal Agents Piscitelli SC Rodvold KA Drug Interactions in Infectious Diseases 2001 Humana Press Inc Totowa, NJ 185 217
29. Palkama VJ Isohanni MH Neuvonen PJ Olkkola KT The effect of intravenous and oral fluconazole on the pharmacokinetics and pharmacodynamics of intravenous alfentanil Anesth Analg 87 1998 190 194
30. Lansdorp D Bressers HP Dekens-Konter JA Meyboom RH Potentiation of acenocoumarol during vaginal administration of miconazole Br J Clin Pharmacol 47 1999 225 226
31. Ortin M Olalla JI Muruzabal MJ Peralta FG Gutierrez MA Miconazole oral gel enhances acenocoumarol anticoagulant activity: a report of three cases Ann Pharmacother 33 1999 175 177
32. Moss AJ Chaikin P Garcia JD Gillen M Roberts DJ Morganroth J A review of the cardiac systemic side-effects of antihistamines: ebastine Clin Exp Allergy Suppl 29 1999 200 205
33. Moss AJ Morganroth J Cardiac effects of ebastine and other antihistamines in humans Drug Saf 21 1999 69 82
34. Pesco-Koplowitz L Hassell A Lee P Zhou H Hall N Wiesinger B Mechlinski W Grover M Hunt T Smith R Travers S Lack of effect of erythromycin and ketoconazole on the pharmacokinetics and pharmacodynamics of steady state intranasal levocabastine J Clin Pharmacol 39 1999 76 85
35. Greenblatt DJ Wright CE von Moltke LL Harmatz JS Ehrenberg BL Harrel LM Ketoconazole inhibition of triazolam and alprazolam clearance: differential kinetic and dynamic consequences Clin Pharmacol Ther 64 1998 237 247
36. Ahonen J Olkkola KT Takala A Neuvonen PJ Interaction between fluconazole and midazolam in intensive care patients Acta Anaesthesiol Scand 43 1999 509 514
37. Backman JT Kivisto KT Olkkola KT Neuvonen PJ The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin Eur J Clin Pharmacol 54 1998 53 58
38. Kivisto KT Lamberg TS Neuvonen PJ Interactions of buspirone with itraconazole and rifampicin: effects on the pharmacokinetics of the active 1-(2-pyrimidinyl)-piperazine metabolite of buspirone Pharmacol Toxicol 84 1999 94 97
39. Kremens B Brendel E Bald M Czyborra P Michel MC Loss of blood pressure control on withdrawal of fluconazole during nifedipine therapy Br J Clin Pharmacol 47 1999 707 708
40. Heinig R Adelmann HG Ahr G The effect of ketoconazole on the pharmacokinetics, pharmacodynamics and safety of nisoldipine Eur J Clin Pharmacol 55 1999 57 60
41. Sandstrom R Knutson TW Knutson L Jansson B Lennernas H The effect of ketoconazole on the jejunal permeability and CYP3A metabolism of (R/S)-verapamil in humans Br J Clin Pharmacol 48 1999 180 189
42. Nair DR Morris HH Potential fluconazole-induced carbamazepine toxicity Ann Pharmacother 33 1999 790 792
43. Sud K Singh B Krishna VS Thennarasu K Kohli HS Jha V Gupta KL Sakhuja V Unpredictable cyclosporin-fluconazole interaction in renal transplant recipients Nephrol Dial Transplant 14 1999 1698 1703
44. Auclair B Berning SE Huitt GA Peloquin CA Potential interaction between itraconazole and clarithromycin Pharmacotherapy 19 1999 1439 1444
45. Raaska K Neuvonen PJ Serum concentrations of clozapine and N-desmethylclozapine are unaffected by the potent CYP3A4 inhibitor itraconazole Eur J Clin Pharmacol 54 1998 167 170
46. Tyle SM Walker D Cole M McSorley L Cholerton S Daly AK Pearson AD Boddy AV The effect of fluconazole on cyclophosphamide metabolism in children Drug Metab Dispos 27 1999 417 421
47. Jalava KM Partanen J Neuvonen PJ Itraconazole decreases renal clearance of digoxin Ther Drug Monit 19 1997 609 613
48. Nishihara K Hibino J Kotaki H Sawada Y Iga T Effect of itraconazole on the pharmacokinetics of digoxin in guinea pigs Biopharm Drug Dispos 20 1999 145 149
49. Tiseo PJ Perdomo CA Friedhoff LT Concurrent administration of donepezil HCl and ketoconazole: assessment of pharmacokinetic changes following single and multiple doses Br J Clin Pharmacol 46 Suppl 1 1998 30 34
50. Kanda Y Kami M Matsuyama T Mitani K Chiba S Yazaki Y Hirai H Plasma concentration of itraconazole in patients receiving chemotherapy for hematological malignancies: the effect of famotidine on the absorption of itraconazole Hematol Oncol 16 1998 33 37
51. Palkama VJ Neuvonen PJ Olkkola KT The CYP 3A4 inhibitor itraconazole has no effect on the pharmacokinetics of iv. fentanyl Br J Anaesth 81 1998 598 600
52. Penzak SR Gubbins PO Gurley BJ Wang PL Saccente M Grapefruit juice decreases the systemic availability of itraconazole capsules in healthy volunteers Ther Drug Monit 21 1999 304 309
53. Kawakami M Suzuki K Ishizuka T Hidaka T Matsuki Y Nakamura H Effect of grapefruit juice on pharmacokinetics of itraconazole in healthy subjects Int J Clin Pharmacol Ther 36 1998 306 308
54. Khoo SM Porter JH Edwards GA Charman WN Metabolism of halofantrine to its equipotent metabolite, desbutylhalofantrine, is decreased when orally administered with ketoconazole J Pharm Sci 87 1998 1538 1541
55. Yasui N Kondo T Otani K Furukori H Mihara K Suzuki A Kaneko S Inoue Y Effects of itraconazole on the steady-state plasma concentrations of haloperidol and its reduced metabolite in schizophrenic patients: in vivo evidence of the involvement of CYP3A4 for haloperidol metabolism J Clin Psychopharmacol 19 1999 149 154
56. Furukori H Kondo T Yasui N Otani K Tokinaga N Nagashima U Kaneko S Inoue Y Effects of itraconazole on the steady-state plasma concentrations of bromperidol and reduced bromperidol in schizophrenic patients Psychopharmacology 145 1999 189 192
57. Polk E Crouch MA Israel DS Pastor A Sadler BM Chittick GE Symonds WT Gouldin W Lou Y Pharmacokinetic interaction between ketoconazole and amprenavir after single doses in healthy men Pharmacotherapy 19 1999 1378 1384
58. De Wit S Debier M De Smet M McCrea J Stone J Carides A Matthews C Deutsch P Clumeck N Effect of fluconazole on indinavir pharmacokinetics in human immunodeficiency virus-infected patients Antimicrob Agents Chemother 42 1998 223 227
59. Kantola T Kivisto KT Neuvonen PJ Effect of itraconazole on the pharmacokinetics of atorvastatin Clin Pharmacol Ther 64 1998 58 65
60. Kantola T Kivisto KT Neuvonen PJ Effect of itraconazole on cerivastatin pharmacokinetics Eur J Clin Pharmacol 54 1999 851 855
61. Kivisto KT Kantola T Neuvonen PJ Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin Br J Clin Pharmacol 46 1998 49 53
62. Neuvonen PJ Kantola T Kivisto KT Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole Clin Pharmacol Ther 63 1998 332 341
63. Gilad R Lampl Y Rhabdomyolysis induced by simvastatin and ketoconazole treatment Clin Neuropharmacol 22 1999 295 297
64. Palkama VJ Neuvonen PJ Olkkola KT Effect of itraconazole on the pharmacokinetics of bupivacaine enantiomers in healthy volunteers Br J Anaesth 83 1999 659 661
65. Arlander E Ekstrom G Alm C Carrillo JA Bielenstein M Bottiger Y Bertilsson L Gustafsson LL Metabolism of ropivacaine in humans is mediated by CYP1A2 and to a minor extent by CYP3A4: an interaction study with fluvoxamine and ketoconazole as in vivo inhibitors Clin Pharmacol Ther 64 1998 484 491
66. Cobb MN Desai J Brown LS Jr Zannikos PN Rainey PM The effect of fluconazole on the clinical pharmacokinetics of methadone Clin Pharmacol Ther 63 1998 655 662
67. Varis T Kaukonen KM Kivisto KT Neuvonen PJ Plasma concentrations and effects of oral methylprednisolone are considerably increased by itraconazole Clin Pharmacol Ther 64 1998 363 368
68. Varis T Kivisto KT Backman JT Neuvonen PJ Itraconazole decreases the clearance and enhances the effects of intravenously administered methylprednisolone in healthy volunteers Pharmacol Toxicol 85 1999 29 32
69. Jaruratanasirikul S Sriwiriyajan S Effect of omeprazole on the pharmacokinetics of itraconazole Eur J Clin Pharmacol 54 1998 159 161
70. Van Puijenbroek EP Egberts AC Meyboom RH Leufkens HG Signalling possible drug-drug interactions in a spontaneous reporting system: delay of withdrawal bleeding during concomitant use of oral contraceptives and itraconazole Br J Clin Pharmacol 47 1999 689 693
71. Sinofsky FE Pasquale SA The effect of fluconazole on circulating ethinyl estradiol levels in women taking oral contraceptives Am J Obstet Gynecol 178 1998 300 304
72. Damkier P Hansen LL Brosen K Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine Br J Clin Pharmacol 48 1999 829 838
73. Herman BD Fleishaker JC Brown MT Ketoconazole inhibits the clearance of the enantiomers of the antidepressant reboxetine in humans Clin Pharmacol Ther 66 1999 374 379
74. Jaruratanasirikul S Sriwiriyajan S Effect of rifampicin on the pharmacokinetics of itraconazole in normal volunteers and AIDS patients Eur J Clin Pharmacol 54 1998 155 158
75. Moreno M Latorre A Manzanares C Morales E Herrero JC Clinical management of tacrolimus drug interactions in renal transplant patients Transplant Proc 31 1999 2252 2253
76. Hairhara Y Makuuchi M Kawarasaki H Takayama T Kubota K Ito M Tanaka H Yoshino H Hirata M Kita Y Kusaka K Sano K Saiura A Ijichi M Matsukura A Watanabe M Hashizume K Nakatsuka T Effect of fluconazole on blood levels of tacrolimus Transplant Proc 31 1999 2767
77. Billaud EM Guillemain R Tacco F Chevalier P Evidence for a pharmacokinetic interaction between itraconazole and tacrolimus in organ transplant patients Br J Clin Pharmacol 46 1998 271 272
78. Furlan V Parquin F Penaud JF Cerrina J Le Roy Ladurie F Dartevelle P Taburet AM Interaction between tacrolimus and itraconazole in a heartlung transplant recipient Transplant Proc 30 1998 187 188
79. Capone D Gentile A Imperatore P Palmiero G Basile V Effects of itraconazole on tacrolimus blood concentrations in a renal transplant recipient Ann Pharmacother 33 1999 1124 1125
80. Brynne N Forslund C Hallen B Gustafsson LL Bertilsson L Ketoconazole inhibits the metabolism of tolterodine in subjects with deficient CYP2D6 activity Br J Clin Pharmacol 48 1999 564 572
81. Gillies J Hung KA Fitzsimons E Soutar R Severe vincristine toxicity in combination with itraconazole Clin Lab Haematol 20 1998 123 124
82. Trapnell CB Klecker RW Jamis-Dow C Collins JM Glucuronidation of 3′-azido-3′-deoxythymidine (zidovudine) by human liver microsomes: relevance to clinical pharmacokinetic interactions with atovaquone, fluconazole, methadone, and valproic acid Antimicrob Agents Chemother 2 1998 1592 1596
83. Greenblatt DJ Von Moltke LL Harmatz JS Mertzanis P Graf JA Durol ALB Counihan M Roth-Schechter B Shader RI Kinetic and dynamic interaction study of zolpidem with ketoconazole, itraconazole, and fluconazole Clin Pharmacol Ther 64 1998 661 671
84. Luurila H Kivisto KT Neuvonen PJ Effect of itraconazole on the pharmacokinetics and pharmacodynamics of zolpidem Eur J Clin Pharmacol 54 1998 163 166
85. Wassmann S Nickenig G Bohm M Long QT syndrome and torsade de pointes in a patient receiving fluconazole Ann Intern Med 38 1999 797
86. Crerar-Gilbert A Boots R Fraenkel D MacDonald GA Survival following fulminant hepatic failure from fluconazole induced hepatitis Anaesth Intensive Care 27 1999 650 652
87. Novelli V Holzel H Safety and tolerability of fluconazole in children Antimicrob Agents Chemother 43 1999 1955 1960
88. Sorensen HT Nielsen GL Olesen C Larsen H Steffensen FH Schonheyder HC Olsen J Czeizel AE Risk of malformations and other outcomes in children exposed to fluconazole in utero Br J Clin Pharmacol 48 1999 234 238
89. Tiboni GM Iammarrone E Giampietro F Lamonaca D Bellati U Di Ilio C Teratological interaction between the bis-triazole antifungal agent fluconazole and the anticonvulsant drug phenytoin Teratology 59 1999 81 87
90. Nolting SK Gupta A Doncker PD Jacko ML Moskovitz BL Continuous itraconazole treatment for onychomycosis and dermatomycosis: an overview of safety Eur J Dermatol 9 1999 540 543
91. Glasmacher A Hahn C Molitor E Marklein G Sauerbruch T Schmidt-Wolf IG Itraconazole though concentrations in antifungal prophylaxis with six different dosing regimens using hydroxypropyl-beta-cyclodextrin oral solution or coated-pellet capsules Mycoses 42 1999 591 600
92. Nguyen AJ Nelson DB Thurn JR Pseudomembranous colitis after itraconazole therapy Am J Gastroenterol 94 1999 1971 1973
93. Foot AB Veys PA Gibson BE Itraconazole oral solution as antifungal prophylaxis in children undergoing stem cell transplantation or intensive chemotherapy for haematological disorders Bone Marrow Transplant 24 1999 1089 1093
94. Verspeelt J Marynissen G Gupta AK De Doncker P Safety of itraconazole in diabetic patients Dermatology 198 1999 382 384
95. Garcia Rodriguez LA Duque A Castellsague J Perez-Gutthann S Stricker BH A cohort study on the risk of acute liver injury among users of ketoconazole and other antifungal drugs Br J Clin Pharmacol 48 1999 847 852